{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:24:19Z","timestamp":1790533459825,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.bpg.2008.12.005","type":"journal-article","created":{"date-parts":[[2009,3,2]],"date-time":"2009-03-02T09:18:46Z","timestamp":1235985526000},"page":"101-112","source":"Crossref","is-referenced-by-count":39,"title":["Serum sickness, encephalitis and other complications of anti-cytokine therapy"],"prefix":"10.1016","volume":"23","author":[{"given":"S\u00e9verine","family":"Vermeire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Van Assche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rutgeerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.bpg.2008.12.005_bib1","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1136\/gut.2005.081950b","article-title":"European evidence based consensus on the diagnosis and management of Crohn's disease: current management","volume":"55","author":"Travis","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2008.12.005_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence based consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.bpg.2008.12.005_bib3","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumour necrosis factor-alpha IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bpg.2008.12.005_bib5","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T\u00a0lymphocytes in Crohn's disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2008.12.005_bib8","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/S0016-5085(03)80497-3","article-title":"Effects of infliximab on apoptosis and reverse signalling of monocytes","volume":"124","author":"Ringheam","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clim.2005.01.007","article-title":"Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model","volume":"115","author":"Shen","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bpg.2008.12.005_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","article-title":"Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept","volume":"21","author":"Shen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2008.12.005_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.MIB.0000194185.69800.07","article-title":"Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model","volume":"12","author":"Shen","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2008.12.005_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.4049\/jimmunol.163.2.1081","article-title":"Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2\/Bax mucosal imbalance","volume":"163","author":"Ina","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.bpg.2008.12.005_bib13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2008.12.005_bib14","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.autrev.2008.01.002","article-title":"Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go","volume":"7","author":"Stefanelli","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.bpg.2008.12.005_bib15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bpg.2008.12.005_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2008.12.005_bib17","article-title":"A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy: the SONIC trial","volume":"103","author":"Sandborn","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"23","key":"10.1016\/j.bpg.2008.12.005_bib18","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib19","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","article-title":"Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease","volume":"98","author":"Regueiro","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2008.12.005_bib20","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bpg.2008.12.005_bib21","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(00)03239-6","article-title":"Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms","volume":"356","author":"Van den Bosch","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2008.12.005_bib22","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2008.12.005_bib23","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance of episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2008.12.005_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib26","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bpg.2008.12.005_bib27","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study","volume":"2","author":"Fidder","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2008.12.005_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"St\u00fcbgen","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bpg.2008.12.005_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.bpg.2008.12.005_bib30","first-page":"A116","article-title":"Excess risk of lymphoproliferative disorders (LPD) in inflammatory bowel diseases (IBD): interim results of the CESAME cohort","volume":"134","author":"Beaugerie","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib31","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2008.12.005_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.bpg.2008.12.005_bib33","author":"US Food and Drug Administration"},{"key":"10.1016\/j.bpg.2008.12.005_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib37","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","article-title":"Immunogenicity of engineered antibodies","volume":"36","author":"Hwang","year":"2005","journal-title":"Methods"},{"key":"10.1016\/j.bpg.2008.12.005_bib39","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2008.12.005_bib40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00054725-200411000-00008","article-title":"Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease","volume":"10","author":"Lamireau","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2008.12.005_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080075","article-title":"Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital","volume":"70","author":"Seiderer","year":"2004","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2008.12.005_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib43","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2008.12.005_bib44","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction","volume":"97","author":"Kugathasan","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2008.12.005_bib45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bpg.2008.12.005_bib46","first-page":"W1347","article-title":"Short and long term safety of remicade (infliximab) in Crohn's disease and rheumatoid arthritis","volume":"122","author":"Louis","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.bpg.2008.12.005_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2036.2003.01411.x","article-title":"Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model","volume":"17","author":"Crandall","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2008.12.005_bib49","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib50","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2008.12.005_bib51","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib52","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2008.12.005_bib53","first-page":"163","article-title":"Immunogenicity of infliximab: how to handle the problem?","volume":"70","author":"Baert","year":"2007","journal-title":"Acta Gastroenterol Belg"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691808001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691808001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T06:22:58Z","timestamp":1684909378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691808001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1521691808001029"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2008.12.005","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}